NCT03808701

Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer

Recombinant Anti-EGFR Monoclonal Antibody（SCT200） in Patients With Advanced Squamous Non-small Cell Lung Cancer : a Phase Ib, Open-label, Multicenter Study

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Sinocelltech Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced squamous non-small cell lung cancer treated after failure of Two chemotherapy regimens (including Platinum-based drugs).

Detailed description

This open label multicenter phase Ib study is designed to evaluate Objective Response Rate (ORR) in Squamous non-small cell Lung cancer treated with anti-EGFR monoclonal antibody SCT200.

Conditions

• Advanced Squamous Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	SCT200	Recombinant Anti-EGFR Monoclonal Antibody

Timeline

• Start date: 2019-03-01
• Primary completion: 2019-12-01
• Completion: 2019-12-01
• First posted: 2019-01-17
• Last updated: 2019-01-17